{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:48:49Z","timestamp":1785894529846,"version":"3.56.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Blood Cancer United","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.018","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:20:48Z","timestamp":1777594848000},"page":"e915-e925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions: Novel Therapies in T-ALL: From CAR-T to Novel Targets"],"prefix":"10.1016","volume":"26","author":[{"given":"Ryan J.","family":"Summers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.04.018_bib0001","unstructured":"American Cancer Society, Cancer facts & figures 2025. 2025. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf. Accessed January 8, 2026."},{"key":"10.1016\/j.clml.2026.04.018_bib0002","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0003","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0005","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0006","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0007","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0008","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0009","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the children's oncology group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0010","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"Moricke","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0011","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0012","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2026.04.018_bib0013","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0014","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2005-04-1754","article-title":"Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol","volume":"107","author":"Vitale","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0016","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood.V114.22.324.324","article-title":"Successful subtype oriented treatment strategies in adult T-all; results of 744 patients treated in three consecutive GMALL studies","volume":"114","author":"Hoelzer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0017","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0018","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/leu.2013.312","article-title":"The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience","volume":"28","author":"Jain","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.018_bib0019","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ejh.12269","article-title":"High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden","volume":"92","author":"Kozlowski","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.leukres.2006.08.004","article-title":"Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates","volume":"31","author":"Yanada","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.04.018_bib0021","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2021-152355","article-title":"First analysis of the UKALL14 randomized trial to determine whether the addition of Nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK\/09\/006)","volume":"138","author":"Rowntree","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0022","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1182\/blood-2023-177696","article-title":"Frontline consolidation with Nelarabine for adults with high-risk T-cell acute lymphoblastic leukemia. Results of the Graall-2014\/T Atriall phase 2 study","volume":"142","author":"Boissel","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2022-158381","article-title":"Results of the risk-adapted, MRD-stratified GMALL trial 08\/2013 in 281 T-ALL \/T-lbl patients: excellent outcome of standard risk thymic T-ALL","volume":"140","author":"Goekbuget","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0024","doi-asserted-by":"crossref","first-page":"11671","DOI":"10.1182\/blood-2022-159139","article-title":"Incorporation of nelarabine (NEL), pegylated asparaginase (PEG) and venetoclax (VEN) in the frontline therapy of adult patients with T-acute lymphoblastic leukemia\/T-lymphoblastic lymphoma (T-ALL\/LBL)","volume":"140","author":"Babakhanlou","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0025","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.clml.2026.04.018_bib0026","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.018_bib0027","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0028","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0029","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3324\/haematol.2018.204545","article-title":"Replacing cyclophosphamide\/cytarabine\/mercaptopurine with cyclophosphamide\/etoposide during consolidation\/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG","volume":"104","author":"Burke","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.04.018_bib0030","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/cncr.31099","article-title":"Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the Children's Oncology Group study AALL1131","volume":"124","author":"Salzer","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0031","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.19.02892","article-title":"Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: children's Oncology Group study AALL1131","volume":"38","author":"Salzer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0032","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0034","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","article-title":"Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia","volume":"131","author":"Petit","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/leu.2015.206","article-title":"Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial","volume":"30","author":"Jenkinson","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.018_bib0036","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.2022018653","article-title":"Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report","volume":"141","author":"Gossai","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0037","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2024-199500","article-title":"Prognostic factors for T-cell acute lymphoblastic leukemia in children and young adults: ALL-T11 study conducted by Japan Children's Cancer Group and Japan adult Leukemia Study Group","volume":"144","author":"Imai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0038","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.15983","article-title":"Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL)","volume":"186","author":"Hofmans","year":"2019","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0039","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2141.2009.07853.x","article-title":"Extended triple intrathecal therapy in children with T-cell acute lymphoblastic leukaemia: a report from the Israeli National ALL-Studies","volume":"147","author":"Stark","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0040","first-page":"1","article-title":"Genomic classification of T-cell acute lymphoblastic leukemia: current paradigms and future biomarkers","volume":"23","author":"Xu","year":"2025","journal-title":"J Natl Comprehens Cancer Netw"},{"key":"10.1016\/j.clml.2026.04.018_bib0041","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2026.04.018_bib0042","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ccr.2011.02.008","article-title":"Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia","volume":"19","author":"Homminga","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2026.04.018_bib0043","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood-2004-10-3900","article-title":"HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL)","volume":"106","author":"Soulier","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0044","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1182\/blood-2007-09-111872","article-title":"The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia","volume":"111","author":"Van Vlierberghe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0045","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2026.04.018_bib0046","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.22.02734","article-title":"The clinicogenomic landscape of induction failure in childhood and young adult T-cell acute lymphoblastic leukemia","volume":"41","author":"O'Connor","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0047","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"P\u00f6l\u00f6nen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.clml.2026.04.018_bib0048","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0049","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.2019004547","article-title":"Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL","volume":"137","author":"Anand","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s43018-024-00863-5","article-title":"A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia","volume":"6","author":"Xu","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0051","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.2023023754","article-title":"NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients","volume":"144","author":"Simonin","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0052","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1182\/bloodadvances.2025017399","article-title":"Prognostic impact of the PredicT-ALL classifier in the AALL0434 trial: a model combining NGS, MRD, and WBC at diagnosis","volume":"9","author":"Simonin","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.04.018_bib0053","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0054","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0055","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1200\/JCO.2010.28.3390","article-title":"Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia","volume":"28","author":"Gutierrez","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0056","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","article-title":"Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15","volume":"156","author":"Inukai","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0057","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11684-012-0224-4","article-title":"Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia","volume":"6","author":"Ma","year":"2012","journal-title":"Front Med"},{"key":"10.1016\/j.clml.2026.04.018_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00254-9","article-title":"Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis","volume":"3","author":"Conter","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0059","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.2023020678","article-title":"Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study","volume":"142","author":"Wood","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0061","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0062","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.26144","article-title":"Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine","volume":"96","author":"Morita","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0063","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0064","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/leu.2009.261","article-title":"Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group","volume":"24","author":"Salzer","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.018_bib0065","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/leu.2009.253","article-title":"Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)","volume":"24","author":"Silverman","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.018_bib0066","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.20.00531","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from children\u2019s oncology Group AALL0434","volume":"38","author":"Hayashi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0067","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI130189","article-title":"Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes","volume":"130","author":"Meyer","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2026.04.018_bib0068","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0069","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clml.2026.04.018_bib115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.2023023155","article-title":"How I treat ETP-ALL in children","volume":"145","author":"Summers","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0071","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2026.04.018_bib0072","series-title":"Blood, ASH Annual Meeting Abstracts","first-page":"20","article-title":"Safety of Palbociclib in combination with chemotherapy in children and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a children's oncology group pilot study","author":"Raetz","year":"2020"},{"key":"10.1016\/j.clml.2026.04.018_bib0073","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.04.018_bib0074","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30609","article-title":"Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a Children's Oncology Group study (AINV18P1)","volume":"70","author":"Raetz","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27062","article-title":"Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Place","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0076","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3324\/haematol.2021.279520","article-title":"Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: a therapeutic advances in Childhood Leukemia Consortium trial (TACL 2014-001)","volume":"107","author":"Tasian","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.04.018_bib0077","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"6142","key":"10.1016\/j.clml.2026.04.018_bib0078","article-title":"Therapeutic targeting of MERTK and BCL-2 in T-cell and early T-precursor acute lymphoblastic leukemia","volume":"14","author":"Summers","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2026.04.018_bib0079","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1158\/1078-0432.CCR-23-0415","article-title":"Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia","volume":"29","author":"Saygin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.04.018_bib0080","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/s41375-023-02057-x","article-title":"Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia","volume":"37","author":"Johansson","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.018_bib0081","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s43018-024-00863-5","article-title":"A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia","volume":"6","author":"Xu","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0082","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","article-title":"Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia","volume":"2","author":"Gocho","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0083","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0084","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0085","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2026.04.018_bib0086","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.3390\/cancers15204957","article-title":"Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers","volume":"15","author":"Xu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2026.04.018_bib0087","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0088","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-19-0551","article-title":"OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL","volume":"25","author":"Evans","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.04.018_bib0089","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41416-018-0014-0","article-title":"AKR1C enzymes sustain therapy resistance in paediatric T-ALL","volume":"118","author":"Bortolozzi","year":"2018","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bcp.2013.12.019","article-title":"A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells","volume":"88","author":"Jamieson","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clml.2026.04.018_bib0091","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/1744666X.2020.1732819","article-title":"Harnessing immunotherapy for pediatric T-cell malignancies","volume":"16","author":"Diorio","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.clml.2026.04.018_bib0092","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1182\/bloodadvances.2020002502","article-title":"CD1a is rarely expressed in pediatric or adult relapsed\/refractory T-ALL: implications for immunotherapy","volume":"4","author":"Leong","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.04.018_bib0093","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.20550","article-title":"Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"47","author":"Raetz","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0094","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates Human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2026.04.018_bib0095","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41419-018-0601-2","article-title":"CD47-ligation induced cell death in T-acute lymphoblastic leukemia","volume":"9","author":"Leclair","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2026.04.018_bib0096","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-018-0768-2","article-title":"MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47","volume":"17","author":"Huang","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clml.2026.04.018_bib0097","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL)","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0098","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0099","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.2021014485","article-title":"Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL","volume":"140","author":"M\u00fcller","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0101","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2023-185875","article-title":"A novel fc-optimized antibody drug conjugate targeting CD7 As a therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"142","author":"Gehlert","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0102","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/biom14010106","article-title":"An anti-CD7 antibody\u2013Drug conjugate target showing potent antitumor activity for T-lymphoblastic leukemia (T-ALL)","volume":"14","author":"Wang","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.clml.2026.04.018_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101097","article-title":"Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies","volume":"32","author":"Cooper","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2026.04.018_bib0104","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0105","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-Human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0106","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1200\/JCO.2022.40.16_suppl.7035","article-title":"Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia\/lymphoma","volume":"40","author":"Zhao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.018_bib0107","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase I clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0108","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ymthe.2024.09.006","article-title":"Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed\/refractory T-ALL: a phase I trial","volume":"33","author":"Zhao","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.clml.2026.04.018_bib0109","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.2025029299","article-title":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial","volume":"146","author":"Pan","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0110","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.2025028387","article-title":"Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed\/refractory T-cell malignancies","volume":"146","author":"Ghobadi","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib0111","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.04.018_bib0112","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa2505478","article-title":"Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia","volume":"394","author":"Chiesa","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.04.018_bib0113","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2026.04.018_bib0114","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2024-203546","volume":"144","author":"Diorio","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.018_bib116","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.clml.2022.07.010","article-title":"SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma","volume":"22","author":"Summers","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:07:48Z","timestamp":1785892068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":116,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S215226502600128X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Novel Therapies in T-ALL: From CAR-T to Novel Targets","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}